These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37902013)

  • 21. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Liu Y; Yang Q; Chen G; Zhou T
    Curr Pharm Des; 2022; 28(40):3289-3304. PubMed ID: 36305135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
    Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
    BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of hyperphosphatemia: the dangers of high PTH levels.
    Bacchetta J
    Pediatr Nephrol; 2020 Mar; 35(3):493-500. PubMed ID: 31696357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Sato H; Goto M; Nishimura G; Morimoto N; Tokushima H; Horii Y; Takahashi N
    Bone; 2023 Feb; 167():116613. PubMed ID: 36395959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney disease.
    Pazianas M; Miller PD
    J Nephrol; 2024 Mar; 37(2):337-342. PubMed ID: 37171706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease.
    Ketteler M; Ambühl P
    J Nephrol; 2021 Oct; 34(5):1405-1418. PubMed ID: 34170509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.
    Egido J; Martínez-Castelao A; Bover J; Praga M; Torregrosa JV; Fernández-Giráldez E; Solozábal C
    Nefrologia; 2016; 36(1):10-8. PubMed ID: 26705959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
    Ureña Torres PA; Bover J; Cohen-Solal M
    Drugs Today (Barc); 2017 Sep; 53(9):489-500. PubMed ID: 29238762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease.
    Bover J; Arana C; Ureña P; Torres A; Martín-Malo A; Fayos L; Coll V; Lloret MJ; Ochoa J; Almadén Y; Guirado L; Rodríguez M
    Nefrologia (Engl Ed); 2021; 41(5):514-528. PubMed ID: 36165134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Salam SN; Khwaja A; Wilkie ME
    Drugs; 2016 May; 76(8):841-52. PubMed ID: 27142279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
    Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
    Koiwa F; Maruta Y
    Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.
    Brandenburg V; Ketteler M
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
    Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM
    Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies.
    Haffner D; Schaefer F
    Pediatr Nephrol; 2013 Apr; 28(4):537-45. PubMed ID: 22893310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.